Remedy Granted Orphan Drug Designation

Remedy Pharmaceuticals’ CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke

NEW YORK, New York, January 17, 2017 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatments to people affected by central nervous system related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational drug, CIRARA, for treatment of severe cerebral edema in patients with acute ischemic stroke.

Link to Press Release